LONDON (Alliance News) - Akers Biosciences Inc on Thursday said it has signed a distribution agreement with US procurement and support services company ADS Inc for the marketing and supply of Akers' rapid diagnostic assays to US government agencies and departments.
The agreement is for an initial term of 18 months and covers Akers' entire product portfolio, though it will focus on its rapid test for Heparin-induced Thrombocytopenia, an allergic condition associated with the commonly used blood-thinner Heparin, generally used in various surgical procedures. It will also focus on its test for determining blood type compatibility for in remote locations and on its range of rapid tests for infectious diseases.
No financial details were revealed on the deal.
"Akers and ADS have identified a number of areas in which US Government departments such as the Department of Defense could benefit significantly from the introduction of the Company's rapid diagnostic assays," said Raymond Akers, Akers' executive chairman.
Akers shares were down 0.6% to 265.00 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
